無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

男性性腺機能低下症 : パイプライン分析

Male Hypogonadism - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 232815
出版日 ページ情報 英文 103 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.75円で換算しております。
Back to Top
男性性腺機能低下症 : パイプライン分析 Male Hypogonadism - Pipeline Review, H1 2019
出版日: 2019年02月01日 ページ情報: 英文 103 Pages
概要

男性性腺機能低下症の主な症状には、倦怠感、体のほてり、不妊、筋肉量の減少、骨粗鬆症があります。男性性腺機能低下症を発症しやすい環境として、HIV/AIDS、クラインフェルター症候群、カルマン症候群、睾丸の負傷、睡眠時無呼吸などがあります。

当レポートでは、男性性腺機能低下症治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

男性性腺機能低下症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

男性性腺機能低下症:企業で開発中の治療薬

男性性腺機能低下症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

男性性腺機能低下症:企業で開発中の製品

男性性腺機能低下症の治療薬開発に従事している企業

  • Antares Pharma, Inc.
  • BIOCAD
  • Clarus Therapeutics, Inc.
  • Diurnal Limited
  • EndoCeutics, Inc.
  • Ferring International Center S.A.
  • Forendo Pharma Limited
  • Lipocine Inc.
  • M et P Pharma AG
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Monosol Rx, LLC
  • Pantarhei Bioscience BV
  • Repros Therapeutics Inc.

男性性腺機能低下症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • BGS-649
  • corifollitropin alfa
  • enclomiphene
  • fispemifene
  • follitropin alfa
  • Kisspeptin-10
  • Libidua
  • LPCN-1111
  • MSS-722
  • T-2
  • TAK-448
  • TBS-1
  • Testavan
  • testosterone
  • testosterone
  • testosterone
  • testosterone
  • testosterone enanthate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate

男性性腺機能低下症:最近のパイプライン動向

男性性腺機能低下症:休止中のプロジェクト

男性性腺機能低下症:開発が中止された製品

男性性腺機能低下症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Male Hypogonadism, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Male Hypogonadism - Pipeline by Allergan Plc, H1 2019
  • Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H1 2019
  • Male Hypogonadism - Pipeline by Diurnal Group Plc, H1 2019
  • Male Hypogonadism - Pipeline by EndoCeutics Inc, H1 2019
  • Male Hypogonadism - Pipeline by Ferring International Center SA, H1 2019
  • Male Hypogonadism - Pipeline by Lipocine Inc, H1 2019
  • Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2019
  • Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H1 2019
  • Male Hypogonadism - Pipeline by Merck & Co Inc, H1 2019
  • Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H1 2019
  • Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H1 2019
  • Male Hypogonadism - Pipeline by Viramal Ltd, H1 2019
  • Male Hypogonadism - Dormant Projects, H1 2019
  • Male Hypogonadism - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Male Hypogonadism, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11083IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H1 2019, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 4, 7, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Male Hypogonadism - Overview
  • Male Hypogonadism - Therapeutics Development
  • Male Hypogonadism - Therapeutics Assessment
  • Male Hypogonadism - Companies Involved in Therapeutics Development
  • Male Hypogonadism - Drug Profiles
  • Male Hypogonadism - Dormant Projects
  • Male Hypogonadism - Discontinued Products
  • Male Hypogonadism - Product Development Milestones
  • Appendix
Back to Top